Abstract:T-cells genetically engineered to express a chimeric antigen receptor (CAR) have shown remarkable results in patients with B-cell malignancies, including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma, with some promising efficacy in patients with multiple myeloma. However, the efficacy of CAR T-cell therapy is still hampered by local immunosuppression and significant toxicities, notably cytokine release syndrome (CRS) and neurotoxicity. The tumor microenvironment (TME) has been identified to play a major role in preventing durable responses to immunotherapy in both solid and hematologic malignancies, with this role exaggerated in solid tumors. The TME comprises a diverse set of components, including a heterogeneous population of various cells and acellular elements that collectively contribute towards the interplay of pro-immune and immunosuppressive signaling. In particular, macrophages, myeloid-derived suppressor cells, regulatory T-cells, and cell-free factors such as cytokines are major contributors to local immunosuppression in the TME of patients treated with CAR T-cells. In order to create a more favorable niche for CAR T-cell function, armored CAR T-cells and other combinatorial approaches are being explored for potential improved outcomes compared to conventional CAR T-cell products. While these strategies may potentiate CAR T-cell function and efficacy, they may paradoxically increase the risk of adverse events due to increased pro-inflammatory signaling. Herein, we discuss the mechanisms by which the TME antagonizes CAR T-cells and how innovative immunotherapy strategies are being developed to address this roadblock. Furthermore, we offer perspective on how these novel approaches may affect the risk of adverse events, in order to identify ways to overcome these barriers and expand the clinical benefits of this treatment modality in patients with diverse cancers. Precise immunomodulation to allow for improved tumor control while simultaneously mitigating the toxicities seen with current generation CAR T-cells is integral for the future application of more effective CAR T-cells against other malignancies.

Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Adoptive T cell therapy for solid tumors: current landscape and future challenges

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

Adoptive Immunotherapy beyond CAR T-Cells

Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy

Cutting-Edge CAR Engineering: Beyond T Cells

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

CAR-T cell technologies that interact with the tumour microenvironment in solid tumours

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Delivery Techniques for Enhancing CAR T Cell Therapy Against Solid Tumors

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

Optimising CAR T therapy for the treatment of solid tumors